Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I Inhibitors
Koji Ando, Al Ozonoff, Shin-Yin Lee, Michael Voisine, Julian-Taylor Parker, Ryota Nakanishi, Sho Nishimura, Jing Yang, Zhao Grace, Ben Tran, Thomas J Diefenbach, Yoshihiko Maehara, Hiroshi Yasui, Tomoyuki Irino, Ravi Salgia, Masanori Terashima, Peter Gibbs, Ramesh K Ramanathan, Eiji Oki, Masaki Mori Show all
CLINICAL COLORECTAL CANCER | CIG MEDIA GROUP, LP | Published : 2021
PURPOSE: The camptothecin (CPT) analogs topotecan and irinotecan specifically target topoisomerase I (topoI) and are used to treat colorectal, gastric, and pancreatic cancer. Response rate for this class of drug varies from 10% to 30%, and there is no predictive biomarker for patient stratification by response. On the basis of our understanding of CPT drug resistance mechanisms, we developed an immunohistochemistry-based predictive test, P-topoI-Dx, to stratify the patient population into those who did and did not experience a response. PATIENTS AND METHODS: The retrospective validation studies included a training set (n = 79) and a validation cohort (n = 27) of gastric cancer (GC) patients,..View full abstract
The Department of Medicine, Boston University Medical School, and Boston University Office of Technology Development supported the publication. The authors also acknowledge the help of Neelabh Bharti for editorial work and for formatting the tables.